慢性肾脏病患者的促红细胞生成素抵抗：当前观点
Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives.
作者信息
Santos Elton Jonh Freitas, Dias Raimunda Sheyla Carneiro, Lima Janielle Ferreira de Brito, Salgado Filho Natalino, Miranda Dos Santos Alcione
机构信息
University Hospital of the Federal University of Maranhão, São Luís, Brazil.
Federal University of Maranhão, São Luís, Brazil.
出版信息
Int J Nephrol Renovasc Dis. 2020 Oct 8;13:231-237. doi: 10.2147/IJNRD.S239151. eCollection 2020.
Abstract
Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin deficiency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefits of treating anemia.
摘要
贫血是慢性肾脏病的常见并发症，其主要原因是促红细胞生成素缺乏。确诊后，治疗从给予促红细胞生成素刺激剂（ESA）开始。然而，一些患者对ESA存在抵抗，这种抵抗需要被逆转，因为它会增加肾病患者的死亡风险。因此，我们对当前文献进行了讨论，内容涉及可改变对此类药物反应的因素以及可考虑用于优化贫血治疗益处的策略。
相似文献
1
Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives.慢性肾脏病患者的促红细胞生成素抵抗：当前观点
Int J Nephrol Renovasc Dis. 2020 Oct 8;13:231-237. doi: 10.2147/IJNRD.S239151. eCollection 2020.
2
A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.一项关于己酮可可碱治疗 CKD 贫血患者促红细胞生成素刺激剂低反应性的随机、安慰剂对照试验：用己酮可可碱处理促红细胞生成素抵抗（HERO）试验。
Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020. Epub 2014 Aug 10.
3
Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.一项关于促红细胞生成素刺激剂决策辅助工具用于肾病贫血治疗的随机对照试验方案。
BMC Nephrol. 2016 Jul 18;17(1):86. doi: 10.1186/s12882-016-0301-z.
4
5
Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.促红细胞生成素可减缓慢性肾病进展：促红细胞生成素直接作用的可能性
Ren Fail. 2016;38(3):390-6. doi: 10.3109/0886022X.2015.1136874. Epub 2016 Jan 29.
6
Erythropoiesis-stimulating agents: past and future.促红细胞生成素：过去与未来。
Kidney Int Suppl. 2007 Nov(107):S1-3. doi: 10.1038/sj.ki.5002480.
7
Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years?慢性肾脏病中的促红细胞生成素：25年来我们学到了什么？
J Formos Med Assoc. 2014 Jan;113(1):3-10. doi: 10.1016/j.jfma.2013.09.004. Epub 2013 Oct 3.
8
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.血清碱性磷酸酶与慢性肾脏病患者对促红细胞生成素刺激剂的原发性抵抗之间的关联：HERO试验的二次分析
Can J Kidney Health Dis. 2015 Aug 18;2:33. doi: 10.1186/s40697-015-0066-5. eCollection 2015.
9
Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.欧洲血液透析患者促红细胞生成素刺激剂使用模式：透析结局和实践模式研究。
Nephron. 2018;140(1):24-30. doi: 10.1159/000490202. Epub 2018 Jun 26.
10
Home Therapy to Reduce Office Visits for Patients with Chronic Kidney Disease and Anemia.家庭治疗以减少慢性肾病和贫血患者的门诊就诊次数。
Nephrol Nurs J. 2017 Jan-Feb;44(1):29-33.
引用本文的文献
1
Engineering Marrow-Mimetic Hydrogel Platforms Enhance Erythropoiesis: A Mechanobiology-Driven Approach for Transfusion Red Blood Cell Production.工程化骨髓模拟水凝胶平台增强红细胞生成：一种用于输血用红细胞生产的机械生物学驱动方法。
Gels. 2025 Jul 31;11(8):594. doi: 10.3390/gels11080594.
2
Comment on: Erythropoietin resistance among pediatric patients on chronic hemodialysis: A cross-sectional study.关于《慢性血液透析患儿的促红细胞生成素抵抗：一项横断面研究》的评论
Pediatr Nephrol. 2025 May 26. doi: 10.1007/s00467-025-06835-w.
3
Progress in the application of novel inflammatory indicators in chronic kidney disease.新型炎症指标在慢性肾脏病中的应用进展
Front Med (Lausanne). 2025 Jan 30;12:1500166. doi: 10.3389/fmed.2025.1500166. eCollection 2025.
4
Ras Guanine Nucleotide-Releasing Protein-4 Inhibits Erythropoietin Production in Diabetic Mice with Kidney Disease by Degrading HIF2A.Ras鸟嘌呤核苷酸释放蛋白4通过降解低氧诱导因子2α抑制糖尿病肾病小鼠促红细胞生成素的产生。
Diabetes Metab J. 2025 May;49(3):421-435. doi: 10.4093/dmj.2024.0398. Epub 2025 Jan 23.
5
Ziltivekimab for anemia and atherosclerosis in chronic kidney disease: a new hope?泽替夫单抗用于慢性肾脏病贫血和动脉粥样硬化：新希望？
J Nephrol. 2025 Mar;38(2):403-414. doi: 10.1007/s40620-024-02117-0. Epub 2024 Oct 25.
6
Evaluation of hepcidin-25/erythroferrone ratio as a potential biomarker for iron utility and erythropoiesis responsiveness to erythropoiesis-stimulating therapy in comparison to immature erythrocyte/reticulocyte parameters in hemodialysis patients.与血液透析患者未成熟红细胞/网织红细胞参数相比，评估铁调素-25/促红细胞生成素比值作为铁利用及红细胞生成对促红细胞生成刺激疗法反应性的潜在生物标志物。
Hematol Transfus Cell Ther. 2024 Nov;46 Suppl 5(Suppl 5):S214-S222. doi: 10.1016/j.htct.2024.04.125. Epub 2024 Aug 21.
7
Short-term effect of low-dose roxadustat combined with erythropoiesis-stimulating agent treatment for erythropoietin-resistant anemia in patients undergoing maintenance hemodialysis.维持性血液透析患者低剂量罗沙司他联合促红细胞生成素治疗抵抗性贫血的短期疗效。
Front Endocrinol (Lausanne). 2024 Jul 1;15:1372150. doi: 10.3389/fendo.2024.1372150. eCollection 2024.
8
A Retrospective Analysis of the Association of Neutrophil-Lymphocyte Ratio (NLR) with Anemia in the Saudi Population.沙特人群中性粒细胞与淋巴细胞比值（NLR）与贫血相关性的回顾性分析
Medicina (Kaunas). 2023 Sep 3;59(9):1592. doi: 10.3390/medicina59091592.
9
Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach to Management of Anaemia in Chronic Kidney Disease.促红细胞生成素缺乏和治疗抵抗中的精准医学：慢性肾脏病贫血管理的新方法
Curr Issues Mol Biol. 2023 Aug 7;45(8):6550-6563. doi: 10.3390/cimb45080413.
10
Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.罗沙司他通过增加产生短链脂肪酸的肠道细菌来减轻接受促红细胞生成剂抵抗的维持性血液透析患者的炎症状态。
Eur J Med Res. 2023 Jul 10;28(1):230. doi: 10.1186/s40001-023-01179-3.
本文引用的文献
1
Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection.炎症与促红细胞生成素低反应性：一种关键联系。
Kidney Med. 2020 May 11;2(3):245-247. doi: 10.1016/j.xkme.2020.05.001. eCollection 2020 May-Jun.
2
Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS).血液透析患者的炎症与促红细胞生成素刺激剂反应：透析预后与实践模式研究（DOPPS）中贫血管理的自身配对纵向研究
Kidney Med. 2020 Mar 26;2(3):286-296. doi: 10.1016/j.xkme.2020.01.007. eCollection 2020 May-Jun.
3
Anemia in chronic kidney disease.慢性肾脏病中的贫血
Rev Assoc Med Bras (1992). 2020 Jan 13;66Suppl 1(Suppl 1):s55-s58. doi: 10.1590/1806-9282.66.S1.55.
4
Clinical practice guideline on undernutrition in chronic kidney disease.慢性肾脏病营养不良临床实践指南
BMC Nephrol. 2019 Oct 16;20(1):370. doi: 10.1186/s12882-019-1530-8.
5
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.缺氧诱导因子激活剂在肾脏性贫血中的临床应用
Adv Chronic Kidney Dis. 2019 Jul;26(4):253-266. doi: 10.1053/j.ackd.2019.04.004.
6
Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin.成人慢性血液透析患者的蛋白质-能量消耗与促红细胞生成素治疗反应之间的关系。
BMC Nephrol. 2019 Aug 14;20(1):316. doi: 10.1186/s12882-019-1457-0.
7
Hemodialysis treatment time versus erythropoietin dose requirement: Reduction in 2,000 units per week by extension of hemodialysis for 1 hour
.血液透析治疗时间与促红细胞生成素剂量需求的关系：每周血液透析时间延长1小时可使促红细胞生成素剂量需求减少2000单位 。
Clin Nephrol. 2019 Oct;92(4):174-179. doi: 10.5414/CN109403.
8
Erythropoiesis-Stimulating Agents and Mortality.促红细胞生成素与死亡率
J Am Soc Nephrol. 2019 Jun;30(6):907-908. doi: 10.1681/ASN.2019030266. Epub 2019 Apr 23.
9
Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.接受血液透析患者的红细胞生成素刺激剂类型与死亡率。
J Am Soc Nephrol. 2019 Jun;30(6):1037-1048. doi: 10.1681/ASN.2018101007. Epub 2019 Apr 23.
10
Safety of Dynamic Intravenous Iron Administration Strategies in Hemodialysis Patients.血液透析患者动态静脉铁剂给药策略的安全性。
Clin J Am Soc Nephrol. 2019 May 7;14(5):728-737. doi: 10.2215/CJN.03970318. Epub 2019 Apr 15.
Zotero 插件